A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Merus B.V.
ALX Oncology Inc.
Varian, a Siemens Healthineers Company
Aktis Oncology, Inc.
Seagen Inc.
Compass Therapeutics
Eli Lilly and Company
BioNTech SE
Mucosa Innovations, S.L.
Boehringer Ingelheim
Astellas Pharma Inc
GlaxoSmithKline
USWM, LLC (dba US WorldMeds)
Seagen Inc.
Pfizer
PDS Biotechnology Corp.
Turning Point Therapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Pfizer
Inhibrx Biosciences, Inc
AstraZeneca
Incyte Corporation
EpiBiologics
Pfizer
Bicara Therapeutics
Dragonfly Therapeutics
Ensem Therapeutics
AstraZeneca
Varian, a Siemens Healthineers Company
PMV Pharmaceuticals, Inc
FindCure Biosciences (ZhongShan) Co., Ltd.
Hoffmann-La Roche
Hoffmann-La Roche
Tubulis GmbH
Eli Lilly and Company
ViroMissile, Inc.
AstraZeneca
Merus B.V.
EMD Serono
Tizona Therapeutics, Inc
Betta Pharmaceuticals Co., Ltd.
IDEAYA Biosciences
Adaptimmune
Merck Sharp & Dohme LLC
Boehringer Ingelheim
Theravectys S.A.
Immunolight, LLC
xCures
Daiichi Sankyo
SN BioScience